DARA BioSciences Inc

Type: Company
Name: DARA BioSciences Inc
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

LHS Helps DARA BioSciences Launch Patient Smartphone App, Gain Targeted Media Coverage

Opportunity: DARA BioSciences launched a smartphone app to provide cancer patients an educational resource to help patients diagnosed with cancer improve oral care and management of oral mucositis in support of Gelclair®, a bioadherent oral rinse ge ... [Published LaVoie Group - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

5 Stocks Under $10 Set to Soar Higher

DELAFIELD, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for $10 a share or less don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline ... [Published The Street Latest - Jul 07 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Biotech Stocks Technical Analysis -- Research on Mast Therapeutics, Sangamo BioSciences, DARA Biosciences, and Idera Pharma

/PRNewswire/ --On Monday, June 30, 2014, the NASDAQ Composite ended at 4,408.18, up 0.23%, the Dow Jones Industrial Average finished the day 0.15% lower at 16,826.60, and the S&P 500 closed at 1,960.23, down 0.04%. During the session five out of ten sectors ... [Published Nasdaq - Jul 01 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

DARA BioSciences' KRN5500 Secures FDA Orphan Drug Designation for Treatment of Multiple Myeloma

DARA BioSciences said that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma.In its release, the Company noted:KRN5500 is a novel, intravenous, non-opioid, ... [Published HighBeam Research - Jun 27 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 2 reports

DARA BioSciences: KRN5500 Secures Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

DARA BioSciences said that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma.According to a release, KRN5500 is a novel, intravenous, non-opioid, ... [Published HighBeam Research - Jun 24 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Is DARA BioSciences' Rebound Sustainable?

10:36 AM| about stocks: DARADARA BioSciences, Inc. (NASDAQ: DARA ) is a Raleigh, North Carolina-based pharmaceutical company specializing in supportive oncology care. The company manufactures and sells a portfolio of drugs for preventive care and treatment ... [Published Seeking Alpha - Jun 19 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix

PR NewswireNEW YORK, June 19, 2014NEW YORKToday, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix ... [Published Digital Journal - Jun 19 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

DARA BioSciences Announces Leadership Transition

Current President and COO Christopher G. Clement Named CEO; David J. Drutz, MD Transitions to Executive Chairman and Retains CMO Role; Haywood D. Cochrane, Jr. Assumes Role of Vice Chairman ... [Published Marketwire - Breaking News Releases - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 1 reports

Why DARA BioSciences (DARA) Stock is Surging Today

NEW YORK (TheStreet) -- DARA BioSciences  surged Monday after the company announced the FDA had granted Orphan Drug Designation to the company's experimental compound KRN5500 for the treatment of multiple myeloma. The stock was up 26.74% to $1.42 at ... [Published The Street Latest - Jun 16 2014]
First reported Jun 03 2014 - Updated Jun 03 2014 - 4 reports

DARA BioSciences Launches Oral Mucositis Care App to Provide Cancer Patients with an Educational Resource to Improve Side Effect Management

RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ... [Published Business Wire Technology News - Jun 03 2014]
First reported May 30 2014 - Updated May 30 2014 - 1 reports

DARA BioSciences, Inc. Announces Pricing of $12.5 Million Public Offering

RALEIGH, NC --(Marketwired - May 30, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA) (the "Company"), an oncology supportive care specialty pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to ... [Published Marketwire - Breaking News Releases - May 30 2014]
First reported Mar 05 2014 - Updated Mar 06 2014 - 3 reports

DARA BioSciences signs Medicare Part D Prescription Drug Agreement with WellCare

DARA BioSciences, an oncology supportive care pharmaceutical company, has announced that the company signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management providing formulary status for the We ... [Published BioPortfolio - Mar 06 2014]

Quotes

Dr. Drutz continued, "We greatly appreciate the expeditious review and approval of this additional KRN5500 orphan designation application by the FDA's Office of Orphan Product Development, which provides an important step towards the potential treatment of multiple myeloma and one of its major complications. This second orphan drug designation underscores the value of this asset and strengthens DARA's resolve and positioning in the ongoing pursuit of partnering opportunities to assist in funding the clinical advancement and development pathway of KRN5500."
DARA BioSciences MD, CEO and chief medical officer David J Drutz said: "It is noteworthy in this regard that up to 20% of myeloma patients have intrinsic peripheral neuropathy, an incidence that increases to the range of 75% in patients treated with neurotoxic drugs such as thalidomide or bortezomib."
BJ's Restaurants - Co. "s holder Luxor Capital increase stake in the Co. to 9.7% from 6.3% and nominates 5 members to the Co." s board. (BBG)

More Content

All (47) | News (23) | Reports (0) | Blogs (22) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
BUZZ-U.S. Stocks on the Move-Apple, Microsoft, ... [Published London South East - Jul 23 2014]
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
LHS Helps DARA BioSciences Launch Patient Smart... [Published LaVoie Group - Jul 08 2014]
5 Stocks Under $10 Set to Soar Higher [Published The Street Latest - Jul 07 2014]
Biotech Stocks Technical Analysis -- Research o... [Published Nasdaq - Jul 01 2014]
DARA BioSciences' KRN5500 Secures FDA Orphan Dr... [Published HighBeam Research - Jun 27 2014]
DARA BioSciences: KRN5500 Secures Orphan Drug D... [Published HighBeam Research - Jun 24 2014]
DARA BioSciences: KRN5500 Secures FDA Orphan Dr... [Published Pharmacy Choice - Jun 24 2014]
Your 56 WRAL TechWire headlines from last week [Published Local Tech Wire - Jun 23 2014]
DARA BioSciences: KRN5500 Gets Orphan Drug Desi... [Published HighBeam Research - Jun 20 2014]
Is DARA BioSciences' Rebound Sustainable? [Published Seeking Alpha - Jun 19 2014]
Agreements, Orphan Drug Designations, and Manag... [Published Digital Journal - Jun 19 2014]
Agreements, Orphan Drug Designations, and Manag... [Published Financial Services - Jun 19 2014]
DARA BioSciences receives FDA orphan drug desig... [Published Pharmaceutical Technology - Jun 18 2014]
DARA BioSciences Announces Leadership Transition [Published Marketwire - Breaking News Releases - Jun 17 2014]
Why DARA BioSciences (DARA) Stock is Surging Today [Published The Street Latest - Jun 16 2014]
US EQUITIES OPENING HEADLINES INCLUDING: US equ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 16 2014]
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Technology News - Jun 03 2014]
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Photo/Multimedia News - Jun 03 2014]
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Health News - Jun 03 2014]
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire News with Multimedia - Jun 03 2014]
Active Equities to Watch -- Research on CSX Cor... [Published PR Newswire: Financial Services - Jun 02 2014]
Why DARA Biosciences (DARA) Stock Is Plunging T... [Published The Street Latest - May 30 2014]
DARA BioSciences, Inc. Announces Pricing of $12... [Published Marketwire - Breaking News Releases - May 30 2014]
Ventrus Biosciences (VTUS) Stock Surges Today [Published The Street Latest - May 29 2014]
DARA Biosciences (DARA) Stock Plunges After Wed... [Published The Street Latest - May 29 2014]
Dara Biosciences (DARA) Stock Explodes Today [Published The Street Latest - May 28 2014]
DARA BioSciences Announces First Quarter 2014 R... [Published Marketwire - Breaking News Releases - May 12 2014]
DARA BioSciences Announces Addition of Soltamox... [Published Marketwire - Breaking News Releases - May 08 2014]
Dara BioSciences to Present at the 12th Annual ... [Published Marketwire - Breaking News Releases - Apr 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ...
DARA BioSciences Announces Leadership Transition [Published Marketwire - Breaking News Releases - Jun 17 2014]
Current President and COO Christopher G. Clement Named CEO; David J. Drutz, MD Transitions to Executive Chairman and Retains CMO Role; Haywood D. Cochrane, Jr. Assumes Role of Vice Chairman ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Technology News - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Photo/Multimedia News - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
DARA BioSciences Launches Oral Mucositis Care A... [Published Business Wire Health News - Jun 03 2014]
RALEIGH, N.C.--(BUSINESS WIRE)--DARA Biosciences today announced the launch of a smartphone app to provide cancer patients an educational resource to help improve oral care and management of oral mucositis. ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Agreements, Orphan Drug Designations, and Manag... [Published Financial Services - Jun 19 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.